BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?

Boston Scientific Corporation (BSX) recently received the Food and Drug Administration’s (FDA) approval to expand the indication for current-generation INGEVITY+ Pacing Leads. Expanded indication for INGEVITY+ Pacing Leads means thin wires will be placed inside the heart that will be connected to an implantable device. It can be used to include conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) when connected to a single or dual-chamber pacemaker.The latest FDA approval enhance ...